DDInter667 DDInter624
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloprolifer
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Erlotinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Efavirenz
Erlotinib {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Erlotinib {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Erlotinib {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is regulated by {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Efavirenz
Erlotinib {u} (Compound) downregulates {v} (Gene) PFN1
PFN1 {u} (Gene) is upregulated by {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Erlotinib {u} (Compound) downregulates {v} (Gene) LDHB
LDHB {u} (Gene) is downregulated by {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Erlotinib {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is regulated by {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Erlotinib {u} (Compound) upregulates {v} (Gene) KIT
KIT {u} (Gene) is downregulated by {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Erlotinib {u} (Compound) downregulates {v} (Gene) LDHB
LDHB {u} (Gene) regulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Erlotinib {u} (Compound) upregulates {v} (Gene) KIT
KIT {u} (Gene) regulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Erlotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Efavirenz (Compound)
Erlotinib (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Efavirenz (Compound)
Erlotinib (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Efavirenz (Compound)
Erlotinib (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is regulated by IKBKB (Gene) and IKBKB (Gene) is upregulated by Efavirenz (Compound)
Erlotinib (Compound) downregulates PFN1 (Gene) and PFN1 (Gene) is upregulated by acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Erlotinib (Compound) downregulates LDHB (Gene) and LDHB (Gene) is downregulated by acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Erlotinib (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is regulated by POLR2I (Gene) and POLR2I (Gene) is downregulated by Efavirenz (Compound)
Erlotinib (Compound) upregulates KIT (Gene) and KIT (Gene) is downregulated by acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Erlotinib (Compound) downregulates LDHB (Gene) and LDHB (Gene) regulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Efavirenz (Compound)
Erlotinib (Compound) upregulates KIT (Gene) and KIT (Gene) regulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Efavirenz (Compound)